NCT06664125View on ClinicalTrials.gov

Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 30, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

September 30, 2025

Conditions
Hyperphosphatemia
Interventions
DRUG

JMKX003002 will be administered orally

tablets for oral administration.

DRUG

Sevelamer carbonate

tablets for oral administration.

Trial Locations (2)

Unknown

NOT_YET_RECRUITING

The First Affiliated Hospital, Sun Yat-sen University, Guangzhou

RECRUITING

The First Affiliated Hospital, Sun Yat-sen University, Guangzhou

Sponsors

Lead Sponsor

Jemincare
All Listed Sponsors
lead

Jemincare

INDUSTRY

NCT06664125 - Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia | Biotech Hunter | Biotech Hunter